Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer
Experimental Therapeutics
-
-
Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery
-
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
-
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
-
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
-
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
-
Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers
-
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
-
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
-
Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery
Categories
Alliance Committee
Browse by Year